#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Pharmacotherapy of heart failure with preserved ejection fraction


Authors: T. Andreasová;  F. Málek
Authors‘ workplace: Kardiocentrum, Nemocnice Na Homolce, Praha
Published in: Kardiol Rev Int Med 2017, 19(2): 128-130

Overview

Heart failure with preserved ejection fraction is a common problem and its treatment is difficult. Disease modifying drugs for heart failure with reduced ejection fraction have not been effective in subjects with preserved ejection fraction. Treatment of ischaemic heart disease, arterial hypertension and rhythm and rate control in atrial fibrillation are the recommended therapeutic principles in this patient population. The research of pharmacotherapy focuses on new pathophysiologic pathways.

Keywords:
heart failure – preserved ejection fraction – pharmacotherapy


Sources

1. Yancy CW, Lopatin M, Stevenson LW et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (AD-HERE) Database. J Am Coll Cardiol 2006; 47(1): 76– 84.

2. Lam CS, Donal E, Kraigher-Krainer E et al. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail 2011; 13(1): 18– 28. doi: 10.1093/ eurjhf/ hfq121.

3. Bhatia RS, Tu JV, Lee DS et al. Outcome of heart fail­ure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355(3): 260– 269.

4. Steinberg BA, Zhao X, Heidenreich PA et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 2012; 126(1): 65– 75. doi: 10.1161/ CIRCULATIONAHA.111.080770.

5. Solomon SD, Dobson J, Pocock S et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart fail­ure. Circulation 2007; 116(13): 1482– 1487.

6. Paulus WJ, van Bal­legoij JJ. Treatment of heart fail­ure with normal ejection fraction: an inconvenient truth! J Am Coll Cardiol 2010; 55(6): 526– 537. doi: 10.1016/ j.jacc.2009.06.067.

7. Mas­sie BM, Carson PE, McMur­ray JJ et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359(23): 2456– 2467. doi: 10.1056/ NEJMoa0805450.

8. Cleland JG, Tendera M, Adamus J et al. The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study. Eur Heart J 2006; 27(19): 2338– 2345.

9. Campbell RT, Jhund PS, Castagno D et al. What have we learned about patients with heart fail­ure and preserved ejection fraction from DIG-PEF, CHARM-Preserved, and I-PRESERVE? J Am Coll Cardiol 2012; 60(23): 2349– 2356. doi: 10.1016/ j.jacc.2012.04.064.

10. Pitt B, Pf­fefer MA, As­sman SF et al. The TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370(15): 1383– 1392. doi: 10.1056/ NEJMoa1313731.

11. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the dia­gnosis and treatment of acute and chronic heart failure. The Task Force for the dia­gnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure As­sociation (HFA) of the ESC. Europ Heart J 2016; 37(27): 2129– 2200. doi: 10.1093/ eurheartj/ ehw128.

12. Špinar J, Hradec J, Špinarová L et al. Souhrn doporučených postupů ESC pro dia­gnostiku a léčbu akutního a chronického srdečního selhání z roku 2016. Cor Vasa 2016; 58(5): e530– e568.

13. McKelvie RS, Komajda M, McMur­ray J et al. I-Preserve Investigators. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. J Card Fail 2010; 16(2): 128– 134. doi: 10.1016/ j.cardfail.2009.09.007.

14. van Veldhuisen DJ, Lins­sen GC, Jaarsma T et al. B-type natriuretic peptide and prognosis in heart fail­ure patients with preserved and reduced ejection fraction. J Am Coll Cardiol 2013; 61(14): 1498– 1506. doi: 10.1016/ j.jacc.2012.12.044.

15. Yusuf S, Pfef­fer MA, Swedberg K et al. The CHARM Investigators and Com­mittees. Ef­fects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362(9386): 777– 781.

16. Flather MD, Shibata MC, Coats AJ et al. The SENIORS Investigators. Randomised trial to determine the ef­fect of nebivolol on mortality and hospital admis­sion in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26(3): 215– 225.

17. Ahmed A, Rich MW, Fleg JL et al. Ef­fect of digoxin on morbidity and mortality in diastolic heart fail­ure trial: the ancil­lary digitalis investigation group. Circulation 2006; 114(5): 397– 403.

18. van Veldhuisen DJ, Cohen-Solal A, Bohm M et al. The SENIORS Investigators. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction. J Am Coll Cardiol 2009; 53(23): 2150– 2158. doi: 10.1016/ j.jacc.2009.02.046.

19. Zamani P, Rawat D, Shiva-Kumar P et al. Ef­fect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction. Circulation 2015; 131(4): 371– 380. doi: 10.1161/ CIRCULATIONAHA.114.012957.

20. Bonderman D, Pretsch I, Steringer-Mascherbauer R et al. Acute hemodynamic ef­fects of riociguat in patients with pulmonary hypertension as­sociated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-control­led, single-dose study. Chest 2014; 146(5): 1274– 1285. doi: 10.1378/ chest.14-0106.

21. Pieske B, Butler J, Filippatos G et al. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). Eur J Heart Fail 2014; 16(9): 1026– 1038. doi: 10.1002/ ejhf.135.

22. Redfield MM, Chen HH, Borlaug BA et al. Ef­fect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013; 309(2): 1268– 1277. doi: 10.1001/ jama.2013.2024.

23. Solomon SD, Ziele M, Pieske B et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised control­led trial. Lancet 2012; 380(9851): 1387– 1395. doi: 10.1016/ S0140-6736(12)61227-6.

Labels
Paediatric cardiology Internal medicine Cardiac surgery Cardiology
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#